PPARA and metabolic dysfunction-associated steatotic liver disease: Although there is currently no approved pharmacotherapy for NAFLD, pharmacological activation of AMPK and PPARα or pharmacological inhibition of its downstream target ACC represent attractive approaches to improve NAFLD17,33,46.